Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Mylan's rejection letter publicly questioned Teva's credibility and the 'industrial logic' of the combination, foreshadowing prolonged hostility rather than…
Bloomberg Intelligence's Sam Fazeli said the deal would help Teva offset Copaxone exposure but warned antitrust risk was material; Wells Fargo's Michael Faerm…
BioPharma Dive characterized the cascading Teva-Mylan-Perrigo M&A drama as a defensive chain reaction in which Mylan's Perrigo bid was partly designed to…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Teva submitted an unsolicited $40B expression of interest to acquire Mylan at $82 per share (cash and stock). Mylan's board unanimously rejected the proposal April 27, 2015. Teva withdrew its proposal July 27, 2015 to focus on the Allergan generics acquisition. Counted here as a publicly announced terminated deal.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Teva Pharmaceutical Industries Ltd. / Mylan N.V. (this deal) | 2015 | $40.0B | — |
| Teva Pharmaceutical Industries Ltd. / Auspex Pharmaceuticals | 2015 | $3.5B | 86 |
| Teva Pharmaceutical Industries Ltd. / Biogal Pharmaceutical | 1995 | — | 82 |
| Teva Pharmaceutical Industries Ltd. / Sicor Inc. | 2003 | $3.4B | 68 |
| Teva Pharmaceutical Industries Ltd. / Ivax Corporation | 2006 | $7.4B | 63 |
| Teva Pharmaceutical Industries Ltd. / Novopharm Limited | 2000 | $600M | 62 |
| Teva Pharmaceutical Industries Ltd. / Ivax Corporation | 2005 | $7.4B | 62 |
← Browse all deals · How we score deals
More: 2015 deals · Teva Pharmaceutical Industries Ltd. deals · Other deals